EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC)
Activating EGFR mutations (exon 19 deletion, L858R) drive ~15% of lung adenocarcinomas in Western populations (30–50% in East Asia). Targeted tyrosine kinase inhibitors (TKIs) are first-line therapy, with ongoing management focused on CNS control and resistance mechanisms.
Diagnostic Workup
- Comprehensive genomic profiling (tissue + liquid biopsy) for EGFR, ALK, ROS1, BRAF, RET, NTRK, MET, KRAS, HER2
- PD-L1 testing (immunotherapy reserved for later lines in EGFR-mutated disease)
- Brain MRI for baseline CNS involvement
- Smoking history (EGFR mutations common in never/light smokers)
First-Line Therapy
- Osimertinib preferred (FLAURA) due to CNS penetration, longer PFS/OS
- Alternative TKIs (gefitinib + chemo, erlotinib + bevacizumab) used in some regions
Resistance & Next Steps
- Re-biopsy (tissue/liquid) at progression to identify resistance mutations (EGFR C797S, MET amplification, HER2 amplification, small cell transformation)
- MET amplification: add MET inhibitor (savolitinib, tepotinib) + osimertinib (combo trials)
- EGFR C797S (trans): combine first- and third-gen TKIs; (cis) requires fourth-gen TKIs (in trials)
- Small cell transformation: treat with platinum-etoposide ± osimertinib
- Oligoprogression: local therapy (stereotactic radiation) while continuing osimertinib
- Systemic progression: platinum doublet ± pemetrexed ± bevacizumab (immunotherapy less effective but considered later with chemo)
- Amivantamab + lazertinib for post-osimertinib disease (CHRYSALIS-2)
- Patritumab deruxtecan (HER3 ADC) for heavily pretreated patients
CNS Metastases
- Osimertinib penetrates CNS; consider SRS for limited lesions
- Leptomeningeal disease may respond to high-dose osimertinib or intrathecal therapy (investigational)
Supportive Care
- Monitor QTc, cardiomyopathy, ILD/pneumonitis risk, diarrhea, rash
- Manage dermatologic toxicity with prophylactic moisturizers, doxycycline, topical steroids
- Smoking cessation, pulmonary rehab, pain management, palliative care integration
Living with EGFR-Mutated NSCLC
- Track TKIs, labs, side effects, imaging, CNS symptoms, genomic test results, and clinical trials
- Maintain cardio-metabolic health, nutrition, and exercise
- Address mental health—fear of recurrence/resistance is common
Complications
- CNS progression, leptomeningeal disease
- Drug-induced ILD/pneumonitis (stop TKI, steroids)
- QT prolongation, cardiomyopathy
- Paraneoplastic syndromes, mood disorders
Research & Future Directions
Fourth-gen TKIs targeting C797S, bispecific EGFR/MET antibodies (amivantamab), KRAS/EGFR combo strategies, and ADCs (HER3) are reshaping the resistance landscape.
Experimental & Emerging Treatments
- CLN-081 & BLU-945: Next-gen TKIs active against multiple resistance mutations.
- Bispecific EGFR/MET Antibodies: Amivantamab combos overcome MET-mediated resistance.
- HER3 ADCs (patritumab deruxtecan): Promising response after multiple lines.
- Liquid Biopsy Digital Twins: AI tracking ctDNA dynamics to predict progression before imaging.
Track EGFR+ NSCLC with Diagnoza.care
Stay Ahead of Resistance Curves – Log TKIs, dose adjustments, imaging results, ctDNA tests, CNS assessments, side effects, supportive therapies, and trial options; capture mood/pain scores; and let the AI companion remind you of scans, labs, and re-biopsy timing.
Medical Disclaimer: Informational only. Work with your thoracic oncologist for genomic testing, targeted therapy sequencing, CNS management, and clinical trial enrollment.
Sources: NCCN NSCLC Guidelines, ASCO, ESMO